Xontogeny

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Neurosterix is a biopharmaceutical company focused on developing innovative medicines for neurological disorders through a unique approach known as allosteric modulation. This method aims to address the limitations of traditional treatments, enhancing efficacy, safety, and tolerability for conditions such as schizophrenia and other neuropsychiatric disorders. By leveraging a specialized drug discovery and development platform, Neurosterix aspires to provide improved therapeutic options for underserved patient populations, ultimately aiming to enhance the quality of life for individuals affected by these challenging conditions.

Delve Bio is a biotechnology company focused on delivering molecular insights to enhance precision patient care. It specializes in the pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF). By providing comprehensive diagnostic solutions in a single test, Delve Bio equips laboratories and clinicians with critical information necessary for identifying both common and rare infectious diseases, thereby facilitating more accurate and timely medical interventions.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.

Peroxitech Therapeutics is a biopharmaceutical company focused on developing PIP-2, a novel peptide drug aimed at reversing acute lung injury (ALI). The company’s approach targets the cytokine storm cascade, a critical process in the development of lung injuries, particularly those resulting from oxygen deprivation. By addressing this underlying mechanism, Peroxitech aims to provide effective treatment options for patients suffering from acute lung conditions.

PolyCore Therapeutics is focused on developing innovative treatments for central nervous system (CNS) disorders, specifically targeting dyskinesia and cognitive impairment. The company aims to create new, affordable therapies that address the side effects associated with the treatment of Parkinson's disease and other neurological conditions. By enhancing patient mobility and quality of life, PolyCore Therapeutics seeks to contribute to more effective management of these disorders while also aiming to reduce overall healthcare costs. Their experienced team of scientists and life sciences professionals is dedicated to advancing research in this critical area of healthcare.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, particularly those with perinatal brain injury. Its lead drug aims to promote the regeneration of myelin-producing oligodendrocytes and reverse white matter injury in premature infants. By providing effective treatments for all babies at risk of brain injury, Tellus Therapeutics seeks to enhance neurodevelopmental outcomes for these vulnerable children.

Peroxitech Therapeutics is a biopharmaceutical company focused on developing PIP-2, a novel peptide drug aimed at reversing acute lung injury (ALI). The company’s approach targets the cytokine storm cascade, a critical process in the development of lung injuries, particularly those resulting from oxygen deprivation. By addressing this underlying mechanism, Peroxitech aims to provide effective treatment options for patients suffering from acute lung conditions.

Shifa Biomedical Corporation is a privately-held biopharmaceutical company based in Malvern, Pennsylvania, established in 2006. The company specializes in the cost-effective discovery and development of small molecule drugs aimed at treating cardiovascular diseases and prostate cancer. Shifa's approach leverages a combination of molecular biology, biochemistry, crystallography, and various screening techniques, including biochemical, cell-based, and virtual methods. The company is staffed by a highly skilled team of scientists with extensive experience in early-stage drug discovery, enabling them to provide valuable research resources and knowledge to medical researchers and biotechnologists. Through its innovative strategies, Shifa Biomedical contributes to advancing drug discovery in critical therapeutic areas.

Nephraegis Therapeutics is a biopharmaceutical company focused on developing innovative treatments for Acute Kidney Injury (AKI). The company is advancing its lead candidate, NPH-022, which aims to prevent and treat AKI, particularly in patients undergoing common cardiovascular and abdominal procedures. Nephraegis Therapeutics utilizes an epoxyeicosatrienoic-related compound that plays a crucial role in regulating various renal and vascular processes. This technology seeks to enhance kidney function and reduce the associated risks of mortality in patients susceptible to acute kidney complications.